ADAM17 and metabolic dysfunction-associated steatohepatitis: Studies using NASH mouse models have shown that ADAM17-mediated MERTK cleavage in liver macrophages decreases during the steatosis to NASH transition and MERTK activation promotes, whereas its inactivation suppresses, liver fibrosis [70].